본문 바로가기

타이틀 타이틀

  • ABOUT
    • General Information
    • CEO Message
    • Organization
    • History
    • Contact Us
  • CELLCOR™
    • CellCor™
    • Documents
    • Inquiry
  • PIPELINE
    • Next Generation Media
    • Clonal Selected MSCs
    • Automated Mass Cell Culture Platform
    • MSC-derived Exosomes
  • GMP
    • NOTICE
      • Notice
      • News
      • Recruit
      • Q&A
      • EN
      • KR
      • EN
      • KR

      ABOUT

      • GENERAL INFORMATION
      • CEO MESSAGE
      • ORGANIZATION
      • HISTORY
      • CONTACT US

      CELLCOR™

      • CELLCOR™
      • Documents
      • INQUIRY

      PIPELINE

      • NEXT GENERATION MEDIA
      • CLONAL SELECTED MSCS
      • AUTOMATED MASS CELL CULTURE PLATFORM
      • MSC-DERIVED EXOSOMES

      GMP

      • GMP

      NOTICE

      • NOTICE
      • NEWS
      • RECRUIT
      • Q&A

      notice

      • Notice
      • News
      • Recruit
      • Q&A

      News

      notice

      한국형 'NIBRT' 도입…"제약바이오 공정 전문인력 양성"

      2021.03.05

      관련링크 http://www.medisobizanews.com/news/articleView.html?idxno=71199 

      PREV

      "보건산업 창업, 수가 보장돼야 혁신적 도전자 나온다"

      NEXT

      안전한 세포 배양 배지 기술개발 성공…해외서 러브콜 쇄도

      Hanwha Biz Metro Bldg., Unit 1305. 242 Digital-ro, Guro-Gu. Seoul, South Korea (08394)

      • TEL (+82-2) 863-1331
      • FAX 02-863-0832
      • E-MAIL xcell@xcell.co.kr

      © 2020 Xcell Therapeutics Inc., Copyright